These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 27403931)

  • 1. Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes.
    Ren Q; Xiao D; Han X; Edwards SL; Wang H; Tang Y; Zhang S; Li X; Zhang X; Cai X; Liu Z; Paul SK; Ji L
    Diabetes Technol Ther; 2016 Sep; 18(9):586-93. PubMed ID: 27403931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors of primary and secondary sulfonylurea failure in type 2 diabetic subjects.
    Wang H; Ren Q; Han X; Chen J; Zhou L; Chen Y; Ji L
    J Diabetes; 2017 Dec; 9(12):1091-1099. PubMed ID: 28233424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.
    Ren Q; Han X; Tang Y; Zhang X; Zou X; Cai X; Zhang S; Zhang L; Li H; Ji L
    Diabetologia; 2014 Apr; 57(4):746-53. PubMed ID: 24356749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
    Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients.
    Arai K; Matoba K; Hirao K; Matsuba I; Takai M; Takeda H; Kanamori A; Yamauchi M; Mori H; Terauchi Y
    Endocr J; 2010; 57(6):499-507. PubMed ID: 20208396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Influence of Genetic Variants and Gene-gene Interaction on Sulfonylurea Efficacy in Type 2 Diabetic Patients.
    Ren Q; Han X; Zhang S; Cai X; Ji L
    Exp Clin Endocrinol Diabetes; 2016 Mar; 124(3):157-62. PubMed ID: 27008632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
    Massi-Benedetti M; Herz M; Pfeiffer C
    Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of gliquidone--short acting sulfonylurea derivative--comparison with glibenclamide and gliclazide].
    Rupprecht E; König E; Limmer J
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():31-2. PubMed ID: 8516203
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.
    Aquilante CL
    Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):359-72. PubMed ID: 20222815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical efficacy of glimepiride].
    Kaneko T; Sakamoto N
    Nihon Rinsho; 1997 Nov; 55 Suppl():152-7. PubMed ID: 9434460
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
    Tirkkonen T; Heikkilä P; Huupponen R; Laine K
    J Intern Med; 2010 Oct; 268(4):359-66. PubMed ID: 20698928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus.
    Aguilar-Salinas CA; Muñoz-Hernandez LL; Cobos-Bonilla M; Ramírez-Márquez MR; Ordoñez-Sanchez ML; Mehta R; Medina-Santillan R; Tusie-Luna MT
    Metabolism; 2013 May; 62(5):638-41. PubMed ID: 23273975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
    Javorsky M; Klimcakova L; Schroner Z; Zidzik J; Babjakova E; Fabianova M; Kozarova M; Tkacova R; Salagovic J; Tkac I
    Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sulfonylureas and daily blood glucose profiles in elderly diabetics].
    Oba K; Koibuchi H; Okazaki K; Igari Y; Inuzuka Y; Yano M; Yamaguchi Y; Ajiro Y; Satoh S; Nagai S; Suzuki T; Nakano H; Metori S
    Nihon Ronen Igakkai Zasshi; 1999 Oct; 36(10):715-20. PubMed ID: 10614126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study.
    Loganadan NK; Huri HZ; Vethakkan SR; Hussein Z
    Pharmacogenomics; 2020 Jun; 21(9):587-600. PubMed ID: 32468916
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.